Rowan T Chlebowski
Overview
Explore the profile of Rowan T Chlebowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
357
Citations
12707
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hendryx M, Manson J, Ostfeld R, Chlebowski R, LeBlanc E, Waring M, et al.
JAMA Netw Open
. 2025 Mar;
8(3):e250609.
PMID: 40048162
Importance: Research investigating weight loss and mortality risk often fails to differentiate between intentional and unintentional weight loss and typically uses body mass index (BMI) as the measure of excess...
2.
Nikolaienko O, Anderson G, Chlebowski R, Jung S, Harris H, Knappskog S, et al.
Clin Epigenetics
. 2025 Feb;
17(1):28.
PMID: 39980037
Background: Constitutional BRCA1 epimutations (promoter hypermethylation) are associated with an elevated risk of triple-negative breast cancer and high-grade serous ovarian cancer. While MGMT epimutations are frequent in colon cancer, glioblastoma,...
3.
Haque R, Chen L, Shi J, Gu Z, Brady-Rogers M, Chlebowski R, et al.
Oncologist
. 2024 Oct;
PMID: 39401323
Background: Little information exists on adverse effects related to opioid use in breast cancer survivors following active cancer treatment, and no studies included an age-matched comparison group. Thus, we examined...
4.
Nelson R, Chlebowski R, Pan K, Rohan T, Mortimer J, Wactawski-Wende J, et al.
Breast Cancer Res Treat
. 2024 Sep;
209(1):49-60.
PMID: 39254768
Background: While the Breast Cancer Risk Assessment Tool (BCRAT) predicts breast cancer incidence, the model's performance, re-purposed to predict breast cancer mortality, is uncertain. Therefore, we examined whether the BCRAT...
5.
Chlebowski R, Aragaki A, Pan K, Haque R, Rohan T, Song M, et al.
J Clin Oncol
. 2024 Aug;
42(30):3537-3549.
PMID: 39173088
Purpose: Menopausal hormone therapy's influence on ovarian and endometrial cancers remains unsettled. Therefore, we assessed the long-term influence of conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) and CEE-alone on...
6.
Chlebowski R, Aragaki A, Pan K, Luo J, Rohan T, Johnson K, et al.
J Clin Oncol
. 2024 Jul;
42(30):3530-3536.
PMID: 39028918
JCO We report long-term colorectal cancer findings from the Women's Health Initiative trial where 16,608 postmenopausal women with a uterus were randomly assigned to daily conjugated equine estrogen (CEE) 0.625...
7.
Chlebowski R, Aragaki A, Pan K, Simon M, Neuhouser M, Haque R, et al.
Cancer
. 2024 May;
130(18):3147-3156.
PMID: 38736319
Background: In the Women's Health Initiative (WHI) randomized trial, dietary intervention significantly reduced breast cancer mortality, especially in women with more metabolic syndrome (MetS) components. Therefore, this study investigated the...
8.
Pan K, Nelson R, Chlebowski R, Piela R, Mullooly M, Simon M, et al.
Breast Cancer Res Treat
. 2024 May;
207(1):65-79.
PMID: 38730133
Background: Whether DCIS is associated with higher breast cancer-specific and all-cause mortality is unclear with few studies in older women. Therefore, we examined DCIS and breast cancer-specific, cardiovascular (CVD)-specific, and...
9.
Manson J, Crandall C, Rossouw J, Chlebowski R, Anderson G, Stefanick M, et al.
JAMA
. 2024 May;
331(20):1748-1760.
PMID: 38691368
Importance: Approximately 55 million people in the US and approximately 1.1 billion people worldwide are postmenopausal women. To inform clinical practice about the health effects of menopausal hormone therapy, calcium...
10.
Chlebowski R, Aragaki A, Pan K, Mortimer J, Johnson K, Wactawski-Wende J, et al.
Breast Cancer Res Treat
. 2024 Apr;
206(1):177-184.
PMID: 38653905
Purpose: In the Women's Health initiative (WHI) randomized clinical trial, conjugated equine estrogen (CEE)-alone significantly reduced breast cancer incidence (P = 0.005). As cohort studies had opposite findings, other randomized...